SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ranbaxy Laboratories in talks to source ingredients for generic Nexium: Report

12 Mar 2014 Evaluate

Ranbaxy Laboratories is reportedly in talks with at least two companies on sourcing ingredients for a generic version of AstraZeneca Plc’s heartburn drug Nexium, after a US ban on shipments from a plant in India. Nexium had global sales last year of $3.87 billion.

Earlier in January, Washington prohibited Ranbaxy, from selling drugs in the United States using ingredients from one of its plants in northern India due to poor manufacturing practices.

Ranbaxy Laboratories is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies.

Peers
Company Name CMP
Sun Pharma Inds. 1619.95
Dr. Reddys Lab 1315.85
Cipla 1294.75
Zydus Lifesciences 927.15
Lupin 2296.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×